SCHEMBL6445430

SCHEMBL6445430

N#Cc1c(OCCN2CCCCC2)nc(N)nc1-c1ccco1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 9/20 0.50
ADORA2A P29274 8/20 0.50
ADORA2B P29275 5/20 0.50
HRH3 Q9Y5N1 3/20 0.43
KCNH2 Q12809 1/20 0.43
CCNA2 P20248 1/20 0.42
CDK2 P24941 1/20 0.42
CCNA1 P78396 1/20 0.42
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 3/20 0.39
HPGD P15428 3/20 0.39
GAA P10253 1/20 0.39
HIF1A Q16665 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
HSD17B10 Q99714 2/20 0.39
LTA4H P09960 1/20 0.39
ADORA3 P0DMS8 3/20 0.39
LMNA P02545 2/20 0.38
POLB P06746 1/20 0.38
SMARCA2 P51531 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6441656 0.91 ADORA1 (0.49) ADORA1ADORA2AADORA2BALDH1A1KDM4E
SCHEMBL6441743 0.81 ADORA1 (0.56) ADORA1ADORA2AADORA2BALDH1A1KDM4E
SCHEMBL6440638 0.81 ADORA2A (0.56) ADORA1ADORA2AADORA2BALDH1A1KDM4E
SCHEMBL6446329 0.80 ALDH1A1 (0.52) ADORA1ADORA2AADORA2BALDH1A1KDM4E
SCHEMBL5046844 0.79 ADORA1 (0.60) ADORA1ADORA2AADORA2BALDH1A1KDM4E
SCHEMBL6449356 0.79 ADORA2A (0.54) ADORA1ADORA2AADORA2BCCNA2CDK2
SCHEMBL5037058 0.79 ADORA2A (0.60) ADORA1ADORA2AADORA2BCCNA2CDK2
SCHEMBL5036930 0.78 ADORA2A (0.59) ADORA1ADORA2AADORA2BALDH1A1KDM4E
SCHEMBL7400221 0.78 ADORA2A (0.46) ADORA1ADORA2AADORA2BCCNA2CDK2
SCHEMBL6441085 0.77 ADORA2A (0.58) ADORA1ADORA2AADORA2BALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA1 3/4885ADORA2A 1/4885ADORA2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.